Company intelligence / Profile preview

Beijing Trimmune Biotech

Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Trimmune Biotech has developed the first personalized neoantigen-specific TCR-T cell therapy, which is in Phase 1 clinical trial. The company has multiple T-cell therapy products including TCR-T, CAR-T, TAL, and TIL therapies in development for solid tumors.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapyCAR-T cell therapyFusion protein
Industry: Biotech

Partnerships

Biocytogen: Collaboration to co-develop TCR-mimic antibody-based cell therapy for intracellular tumor-associated antigensHCW Biologics: License and Co-Development Agreement for HCW11-006 for in vivo applications, with exclusive license in designated territories

Beyond the preview

Go deeper on Beijing Trimmune Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Trimmune Biotech.

Explore the full profile